Progenity Inc (PROG)
$1.24
0.09 (6.77%)
PROG Stock Quote Delayed 30 Minutes
Progenity Stock’s Hype Cycle Is Over, It Needs Results
Progenity spent 2021 reinventing itself, dumping its testing laboratory, hiring a new CEO, and refocusing on its patent portfolio. PROG stock hopes its patent portfolio can result in new tests and treatments for disease, but mining it will take time and money.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
203.05M
PE Ratio
-0.33
EPS
-3.78
Volume (Avg. Vol.)
11.54M
Day's Range
$1.23 - $1.36
52-Week Range
$0.66 - $7.86
Dividend & Yield
N/A (N/A)
PROG Stock Predictions, Articles, and Progenity Inc News
Range of Therapeutic Products Puts Progenity Above Peers
Biotechnology sector traders should put PROG stock on their radars as it has demonstrated the ability to make 2x, 3x moves and more.
The Long-Term Story Still Holds True for Volatile Progenity Stock
Biotech play PROG stock will likely continue to move wildly, until it makes breakthroughs with its promising pipeline.
Progenity Stock Needs to Fall Further to Become a Viable Investment
The money has already been made on PROG stock and there is little incentive to invest in this one beyond the potential of a short squeeze.
Progenity Stock Looks Poised to Become a Big Winner
Progenity's products are well-positioned to save a great deal of time and money, while the valuation of PROG stock is reasonable.
Capital Raises Add Confidence to Fast-Moving Biotech Progenity
Unique delivery of GI-disease treatments -- along with multiple liquidity infusions -- should help to ease the concerns of PROG stock holders.
Progenity Has Too Many Problems, Not Enough Money?
One of the many recent IPOs since the Covid-19 pandemic, PROG stock has encountered numerous setbacks to be a comfortable ride. With their partnership with Avero Diagnotics, management is currently refocusing efforts and resources, seeking "strategic alternatives" to help the company soar.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!
4 New Patents Add to Progenity’s Appeal
PROG stock has had its fair share of ups and downs. With a major executive-level change, however, Progenity looked poised for progress.
PROG Stock Alert: What Is Going on With Progenity Today?
Popular short play Progenity is enjoying a good week. PROG stock is gaining as investors continue to bet against short sellers.
With Progenity, What Is Pumped Will Be Dumped
Progenity came public as a genetic testing company in 2020, then closed the lab and is doing early-stage clinical trials.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday.
Progenity: Don’t Bet on This Biotech Firm Yet
PROG Stock IPOed in 2020 to develop a genetic testing business. Progenity has now shut that business down, leaving shareholders in a lurch.
I Almost Confused Progenity With Progressive Insurance
Only a meme stock could garner the kind of investor interest PROG stock has with no chance of returning to 2020 revenue levels anytime soon.
Progenity Is a Risky Bet Due to Its Restructuring Gamble
Progenity's plan to ditch most of its current portfolio and double down on R&D may come back to bite it later. Avoid PROG stock for now.
Say Goodbye — Not Good Buy — to the Progenity Short Squeeze
Progenity may be onto something big, but today it's just a meme stock. Following earnings, PROG stock is in trouble.
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
Progenity Offers Nothing That Dozens of Other Biotechs Don’t
PROG stock should suffer dilution but its IP strength will lure some in nonetheless. It looks like a biotech to avoid.
Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop
Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees.
